5 documents found, page 1 of 1
Decompressive surgery in cerebral venous sinus thrombosis due to vaccine‐induce...
Krzywicka, Katarzyna; de Sousa, Diana Aguiar; Cordonnier, Charlotte; Bode, Felix J.; Field, Thalia S.; Michalski, Dominik; Pelz, Johann; Skjelland, MonaBackground and purpose: Cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia (CVST-VITT) is an adverse drug reaction occurring after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. CVST-VITT patients often present with large intracerebral haemorrhages and a high proportion undergoes decompressive surgery. Clinical characteristics, therapeutic manag...
Endovascular treatment of cerebral sinus thrombosis due to vaccine-induced immu...
Weller, Johannes; Krzywicka, Katarzyna; van de Munckhof, Anita; Dorn, Franziska; Althaus, Katharina; Bode, Felix J.; Bandettini di Poggio, MonicaIntroduction: There is little data on the role of endovascular treatment (EVT) of cerebral venous sinus thrombosis (CVST) due to vaccine-induced immune thrombotic thrombocytopenia (VITT). Here, we describe clinical characteristics and outcomes of CVST-VITT patients who were treated with EVT. Patients and methods: We report data from an international registry of patients who developed CVST within 28 days of SARS...
Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocyto...
Krzywicka, Katarzyna; van de Munckhof, Anita; Zimmermann, Julian; Bode, Felix J.; Frisullo, Giovanni; Karapanayiotides, Theodoros; Pötzsch, BerndCerebral venous thrombosis (CVT) is the most common and severe manifestation of vaccine-induced immune thrombotic thrombocytopenia (VITT), which is a rare side effect of the SARS-CoV-2 vaccine ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca/Oxford). The absolute risk of VITT and VITT-related CVT is estimated at 20 and 8 per million first doses of ChAdOx1 nCoV-19, respectively. So far, no definite VITT cases occurring a...
Outcomes of cerebral venous thrombosis due to vaccine-induced immune thrombotic...
van de Munckhof, Anita; Lindgren, Erik; Kleinig, Timothy J.; Field, Thalia S.; Cordonnier, Charlotte; Krzywicka, Katarzyna; Poli, SvenBackground: Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe condition, with high in-hospital mortality rates. Here, we report clinical outcomes of patients with CVT-VITT after SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination who survived initial hospitalization. Methods: We used data from an international registry of patients ...
Management of cerebral venous thrombosis due to adenoviral COVID-19 vaccination
Scutelnic, Adrian; Krzywicka, Katarzyna; Mbroh, Joshua; van de Munckhof, Anita; van Kammen, Mayte Sánchez; de Sousa, Diana Aguiar; Lindgren, ErikObjective: Cerebral venous thrombosis (CVT) caused by vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus-based severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines. In March 2021, after autoimmune pathogenesis of VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non-heparin anticoagulants, and avoidance...